As we have reported previously, vision loss due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) lawsuits involving Ozempic and Mounjaro are being filed. These NAION lawsuits seek legal compensation for the person suffering from this serious eye side effect injury. Ozempic NAION lawsuits are filed against Novo Nordisk. Mounjaro NAION lawsuits are filed against Eli Lilly. Those drug injury cases would only be filed against these pharmaceutical companies – and not against patients’ doctors – because there are no warnings about NAION vision loss for Ozempic or Mounjaro in their current drug labels.
As regards the NAION lawsuits involving Ozempic and Mounjaro that are filed in federal courts, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a December 2025 ruling that established a new federal court MDL case for these NAION lawsuits. It is called IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy [NAION] Products Liability Litigation, MDL No. 3163.
In addition to NAION lawsuits involving Ozempic and Mounjaro, this relatively new MDL No. 3163 federal court lawsuits “consolidation” — which is not the same as a “class action”, but often confused with such — includes NAION lawsuits for patients who used Wegovy or Rybelsus (Novo Nordisk) and Zepbound (Eli Lilly).
For these NAION lawsuits, we offer an online case evaluation service that is free and confidential, and without obligation:
- Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
- Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
If you would rather speak with Tom Lamb about your possible NAION eye side effect drug injury lawsuit, call him at 910-256-2971.
In closing, we are investigating NAION lawsuits that would be filed against the pharmaceutical drug company Eli Lilly (Mounjaro and Zepbound) or Novo Nordisk (Ozempic, Wegovy, and Rybelsus).
Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation